Sarah Boyce, President and CEO at Avidity Biosciences, Inc. (RNA), sold 8,576 shares at $72.23 ($619K) on 2026-01-07, disclosed to the SEC on 2026-01-09.
Scheduled sale ($619k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RNA | SELL | 2025-08-29 | $1.2M | — | Filing → |
| RNA | SELL | 2025-03-21 | $2.0M | — | Filing → |
| RNA | SELL | 2025-01-23 | $595K | — | Filing → |